Tatsuoka, Yoshihisa
Takeshima, Takao
Ozeki, Akichika
Matsumura, Taka
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study
https://doi.org/10.1007/s40120-024-00602-z
Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
https://doi.org/10.1007/s40120-023-00534-0
Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
https://doi.org/10.1007/s40120-022-00410-3
Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
https://doi.org/10.1007/s40120-021-00236-5
Funding for this research was provided by:
Eli Lilly Japan
Article History
Received: 7 December 2020
Accepted: 19 February 2021
First Online: 9 April 2021